Latest Diamyd Medical News & Updates

See the latest news and media coverage for Diamyd Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.

Diamyd Medical

Clinical-stage developer of precision therapies for type 1 diabetes

diamyd.com

Headquarters: Stockholm, Sweden
Company type: Public company
Number of employees: 50–54
Industry: Pharmaceuticals

Last updated October 7

Latest news about Diamyd Medical

In short: Diamyd Medical halted Phase 3 DIAGNODE-3 after failure, began strategic review and cost cuts

Company announcements

October 7 Diamyd Medical

Diamyd Medical publishes annual report for 2025/26 with focus on retogatein

The company reports a net loss and strengthens its position with new patents and a new CFO. The development of the drug retogatein continues towards the market.

September 24 Diamyd Medical

Diamyd Medical publishes long-term results for retogarelin

The study shows that the treatment delays insulin-dependent type 1 diabetes by more than five years in genetically defined children.

July 27 Diamyd Medical

Diamyd Medical ends DIAGNODE-3 after lack of benefit

The interim analysis of 174 participants did not show statistical significance, and no safety issues were identified. The company conducted a structured review that identified several factors for future studies.

June 25 Diamyd Medical

Diamyd Medical's CEO discusses the company's difficult period

He wrote an unusually candid letter in the Q3 report about stepping in as CEO during a crossroads.

Media coverage

October 6 MarketScreener

Diamyd Medical AB Reports Earnings Results for the Full Year Ended August 31, 2026

Diamyd Medical AB (publ) reported earnings results for the full year ended August 31, 2026. For the full year, the company reported sales was SEK...

September 24 Marketscreener

Diamyd Medical: Retogatein delays insulin-dependent type-1 diabetes by more than 5 years

Retogatein from Diamyd Medical delayed the onset of insulin-dependent type-1 diabetes by more than 5 years. The long-term follow-up now published in Diabetologia...

July 27 Finanznachrichten

Diamyd Medical AB (publ): Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis

Review identifies potential contributing factors and informs future development considerations; no new safety concerns identified. The pre-specified interim analysis included 174 of 321 enrolled parti...

June 24 Dagens industri

Operating profit plummeted for struggling Diamyd

Research company Diamyd Medical reports an operating result of -127.2 million kronor (-48.1) for the third quarter of 2026.

Never miss news about Diamyd Medical

Track Diamyd Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Diamyd Medical competitors & trending companies

Browse news for competitors to Diamyd Medical and other trending companies.